aflibercept high-dose
Selected indexed studies
- Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema. (Curr Opin Ophthalmol, 2025) [PMID:39937692]
- Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. (JAMA Ophthalmol, 2023) [PMID:37535382]
- Aflibercept high-dose (8mg) related intraocular inflammation (IOI) - a case series. (BMC Ophthalmol, 2024) [PMID:39623439]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema. (2025) pubmed
- Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. (2024) pubmed
- Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial. (2023) pubmed
- Aflibercept high-dose (8mg) related intraocular inflammation (IOI) - a case series. (2024) pubmed
- Initial Functional and Anatomical Outcomes of High-dose Aflibercept 8 mg in Exudative Neovascular Age-related Macular Degeneration. (2025) pubmed
- High dose aflibercept treatment in naive neovascular age-related macular degeneration. (2025) pubmed
- Efficacy and Safety of High-Dose Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration (nAMD): A Systematic Review. (2025) pubmed
- High‑dose aflibercept injection has striking effects on myopic choroidal neovascularization. (2023) pubmed
- Age-related macular degeneration. (2018) pubmed
- HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. (2018) pubmed